Curing blindness through regenerative cell therapies. We replace what is lost.
StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.
We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.
The most innovative startup in health and life sciences in Europe at BioFit, 2020
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Latest news
22/03/2024
StemSight moves to second phase of EIC Accelerator
As an innovative technology company focused on creating lasting benefits to the European health ecosystem, StemSight is a prime candidate for EU's EIC Accelerator funding. This highly competitive funding scheme requires two application phases, and a final interview. We are glad to announce that we have received very positive evaluation from the four independent evaluators on our first phase application and are eager to move to the next step!
13/03/2024
Laura Koivusalo finalist for Young Researcher Entrepreneur of the Year
Our CEO Laura has been nominated and selected as one of the three finalists for KAUTE Foundation's Young Research Entrepreneur of the Year award. This is already her second nomination for the award.
19/03/2024
Laura Koivusalo speaks at Advanced Therapies in London
Our CEO Laura attends the Advanced Therapies event in London on March 19-20. Laura joins other prominent Cell and Gene Therapy leaders in an expert panel on Autologous vs. Allogeneic approaches in cell therapy.
17/02/2024
StemSight prominently featured in Yle news piece
The premier news outlet in Finland, Yle, did an extensive news feature article about StemSight, including a video filmed at our research labs. The video was also aired in local news.
Investor presentation
We are in discussions with international biotech and life science investors and corporates to get our life-changing products to first patients.
Curious?
Want to know more?
Interested to join our next investment round?
Want to hear about our latest developments?
Just thought of someone we absolutely need to meet?
Send us a message!